AG
ALDR

Artal Group’s Alder Biopharmaceuticals ALDR Stock Holding History

Artal Group’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-850,000
Closed -$10M – 119
2019
Q2 		$10M Buy
850,000
+350,000
+70% +$4.24M 0.4% 51
2019
Q1 		$6.83M Buy
500,000
+300,000
+150% +$3.89M 0.28% 65
2018
Q4 		$2.05M Buy
+200,000
New +$2.56M 0.08% 94
2018
Q1 		– Sell
-500,000
Closed -$5.72M – 144
2017
Q4 		$5.72M Hold
500,000
– – 0.09% 65
2017
Q3 		$6.13M Buy
500,000
+200,000
+67% +$2.09M 0.11% 58
2017
Q2 		$3.44M Hold
300,000
– – 0.06% 78
2017
Q1 		$6.24M Buy
+300,000
New +$6.64M 0.14% 55

Other funds holding ALDR

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $494M AUM 23.45% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Artal Group's ALDR Position: Q3 2019 in Review

Artal Group sold out of Alder Biopharmaceuticals (ALDR) in Q3 2019, closing a stake of 850,000 shares — an estimated $10M sold.

Artal Group first reported a position in ALDR in Q1 2017 and held it in 7 quarters. The position peaked at $10M in Q2 2019. 143 funds tracked by Wall St. Rank hold ALDR as of Q3 2019.

  • Artal Group reported no remaining Alder Biopharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Artal Group sold 850,000 Alder Biopharmaceuticals shares in Q3 2019, an estimated $10M.
  • Artal Group first reported a position in Alder Biopharmaceuticals in Q1 2017 and held it in 7 quarters.
  • Artal Group's Alder Biopharmaceuticals position peaked at $10M in Q2 2019.
  • 143 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q3 2019.

Based on Artal Group's 13F filing for Q3 2019, filed 14 Nov 2019.